Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

AstraZeneca
QuintilesIMS
Fish and Richardson
Queensland Health
Moodys
Merck
Fuji
US Department of Justice
Argus Health

Generated: December 14, 2018

DrugPatentWatch Database Preview

MORPHABOND ER Drug Profile

« Back to Dashboard

When do Morphabond Er patents expire, and what generic alternatives are available?

Morphabond Er is a drug marketed by Daiichi Sankyo Inc and is included in one NDA. There is one patent protecting this drug.

This drug has nineteen patent family members in eight countries.

The generic ingredient in MORPHABOND ER is morphine sulfate. There are twenty-three drug master file entries for this compound. Fifty-four suppliers are listed for this compound. Additional details are available on the morphine sulfate profile page.

Drug patent expirations by year for MORPHABOND ER
Pharmacology for MORPHABOND ER
Drug ClassOpioid Agonist
Mechanism of ActionFull Opioid Agonists
Medical Subject Heading (MeSH) Categories for MORPHABOND ER
Synonyms for MORPHABOND ER
(4R,4aR,7S,7aR,12bS)-3-methyl-2,4,4a,7,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinoline-7,9-diol;sulfuric acid;pentahydrate
(5alpha,6alpha)-7,8-didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol, hydrogen sulfate (2:1)
1095-53-0
17-methyl-7,8-didehydro-4,5alpha-epoxymorphinan-3,6-diol sulfate (2:1)
17-methyl-7,8-didehydro-4,5alpha-epoxymorphinan-3,6-diol sulfate (2:1) pentahydrate
178935-96-1
4,5-alpha-Epoxy-17-methylmorphinan-3,5-alpha-diol sulfate hydrate (2:1:5)
57-27-2 (Parent)
6211-15-0
64-31-3
66591-53-5
7,8-Didehydro-4,5alpha-epoxy-17-methylmorphinan-3,6alpha-diol sulfate (2:1) (salt) pentahydrate
92004-19-8
Apomorphine impurity B (morphine sulfate), European Pharmacopoeia (EP) Reference Standard
Arymo ER
Astramor PH (TN)
Astramorph
Astramorph PF
Avinza
Avinza (TN)
CAS-6211-15-0
CHEBI:50731
CHEBI:7003
CHEMBL2096625
CHEMBL2103744
D00842
Depodur (TN)
Di(morphine) dihydrogen sulfate pentahydrate
DSSTox_CID_28840
DSSTox_GSID_48914
DSSTox_RID_83109
DTXSID1048914
DTXSID4023830
Duramorph
Duramorph PF
DY70C97N30
EINECS 200-582-8
Kadian (TN)
Kapanol
l-Morphine sulfate
Morphabond
Morphinan-3,6-alpha-diol, 7,8-didehydro-4, 5-alpha-epoxy-17-methyl-, sulfate
Morphinan-3,6-diol, 7,8-didehydro-4,5-epoxy-17-methyl- (5alpha,6alpha)-, sulfate (2:1) (salt)
Morphinan-3,6-diol, 7,8-didehydro-4,5-epoxy-17-methyl-(5-alpha,6-alpha)-, sulfate (2:1) (salt), pentahdrate
Morphinan-3,6-diol, 7,8-didehydro-4,5-epoxy-17-methyl, (5alpha,6alpha)-, sulfate (2:1) (salt), pentahydrate
Morphinan-3,6alpha-diol, 7,8-didehydro-4,5alpha-epoxy-17-methyl-, sulfate (2:1) (salt)
Morphinan-3,6alpha-diol, 7,8-didehydro-4,5lpha-epoxy-17-methyl-, sulfate (2:1) (salt), pentahydrate
Morphine Extra-Forte
Morphine for system suitability, European Pharmacopoeia (EP) Reference Standard
Morphine Forte
Morphine H.P
Morphine hemi[sulfate pentahydrate]
Morphine Hemisulfate Pentahemihydrate
Morphine Hemisulphate Pentahemihydrate
Morphine sulfat, European Pharmacopoeia (EP) Reference Standard
MORPHINE SULFATE
Morphine Sulfate (anhydrous)
Morphine sulfate (USP)
Morphine sulfate [USP:JAN]
Morphine sulfate hydrate
Morphine sulfate hydrate (JP17)
MORPHINE SULFATE NARCOTIC ANALGESIC
Morphine sulfate pentahydrate
Morphine sulfate salt pentahydrate
Morphine sulfate salt pentahydrate, analytical standard
Morphine sulfate salt solution
Morphine sulfate salt solution, 1.0 mg/mL in methanol, drug standard
morphine sulfate--dea schedule ii item
Morphine sulfate, United States Pharmacopeia (USP) Reference Standard
Morphine sulphate
Morphine sulphate (2:1)
Morphine sulphate pentahydrate
Morphine, hemisulfate
MORPHINIUMCHLORIDE
MS contin (TN)
MST-1 Continus
NCGC00247707-01
NIH 0001
NIH 10753
NSC 11441
Oramorph SR
SCHEMBL29316
Skenan
Tox21_112861
UNII-DY70C97N30
UNII-X3P646A2J0
X3P646A2J0

US Patents and Regulatory Information for MORPHABOND ER

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Daiichi Sankyo Inc MORPHABOND ER morphine sulfate TABLET, EXTENDED RELEASE;ORAL 206544-001 Oct 2, 2015 RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Daiichi Sankyo Inc MORPHABOND ER morphine sulfate TABLET, EXTENDED RELEASE;ORAL 206544-004 Oct 2, 2015 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Daiichi Sankyo Inc MORPHABOND ER morphine sulfate TABLET, EXTENDED RELEASE;ORAL 206544-002 Oct 2, 2015 RX Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Daiichi Sankyo Inc MORPHABOND ER morphine sulfate TABLET, EXTENDED RELEASE;ORAL 206544-004 Oct 2, 2015 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Daiichi Sankyo Inc MORPHABOND ER morphine sulfate TABLET, EXTENDED RELEASE;ORAL 206544-001 Oct 2, 2015 RX Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Healthtrust
Express Scripts
US Army
Moodys
Deloitte
Daiichi Sankyo
Queensland Health
Cipla
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.